<DOC>
	<DOCNO>NCT01914965</DOCNO>
	<brief_summary>The influence bupropion compare placebo change apathy quantify apathy evaluation scale ( AES-I , I [ informant ] friend family member familiar daily activity subject ) patient HD ten ( 10 ) week treatment .</brief_summary>
	<brief_title>Apathy Cure Through Bupropion Huntington 's Disease</brief_title>
	<detailed_description>The safety tolerability Bupropion HD . The influence Bupropion compare placebo : - change apathy quantify AES-C ( clinician ) AES-S ( self ) , - change motor symptom ( UHDRS ) quantitative grip force motor assessment , - change cognitive symptom ( UHDRS MMSE ) , - change psychiatric symptom ( UHDRS , HADS ) , - change activity daily live ( UHDRS ) , - change NPI caregiver ' distress score ( NPI-D ) , - change ventral striatal ventromedial prefrontal activation response reward paradigm quantify fMRI .</detailed_description>
	<mesh_term>Huntington Disease</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>1 . Verified HD mutation carrier age 25 75 year ( inclusive ) first dose 2 . Apathetic diagnose SCIAD criterion 3 . Stable concomitant medication ( change medication last six week prior inclusion ) 4 . Written inform consent prospective study participant conduct trialrelated procedure . Participant must able make informed decision whether participate study 5 . Patient caregiver ( family member friend ) , live close relationship patient willing give write informed consent ( caregiver ) performance trialrelated procedure Exclusion criterion : 1 . Pregnant nursing woman 2 . Active suicidality base answer `` yes '' question 4 5 ColumbiaSuicide Severity Rating Scale ( baseline version ) 3 . Woman childbearing potential , use highly effective method contraception define method Pearl Index &lt; 1 oral , topical injected contraception , IUD , contraceptive vaginal ring , double barrier method diaphragm condom spermicide ) surgically sterile ( via hysterectomy , ovariectomy bilateral tubal ligation ) least one year postmenopausal 4 . Male use acceptable barrier method contraception donate sperm screen three month follow treatment 5 . Presence history medically controllable disease ( e.g . uncontrolled arterial hypertension diabetes mellitus ) 6 . Presence history seizure diagnose epilepsy history severe head trauma ( contusion ) CNS tumor 7 . Clinical significant renal ( calculated creatine clearance &lt; 60 ml/min ) hepatic dysfunction 8 . Clinical significant depression define NPI depression score ( score â‰¥4 point ) screen 9 . Schizophreniform psychosis within last 6 month prior first dose 10 . History anorexia bulimia 11 . Severe cognitive disorder define score &lt; 18 Mini Mental State Examination ( MMSE ) screen 12 . Marked chorea ( UHDRS 4 ) face , BOL , trunk extremity 13 . Treatment neuroleptic tiapride , MAOB inhibitor , amantadine , levodopa , D D , Lamphetamine psychostimulants like methylphenidate , modafinil atomoxetine within 1 month prior first dose 14 . Known hypersensitivity reaction associate bupropion , gelatine , lactose magnesium stearate 15 . Clinically relevant abnormal finding ECG , vitals , physical examination laboratory value screen could interfere objective study safety subject judge investigator 16 . Acute disease state ( e.g . nausea , vomit , fever , diarrhoea , infection ) within 7 day first dose 17 . Definite suspect personal history family history adverse reaction hypersensitivity trial compound ( compound similar structure ) 18 . Presence illicit drug and/or alcohol abuse 19 . Participation another investigative drug trial within 2 month donation blood within 12 week prior first dose trial 20 . Subjects unlikely compliant attend schedule clinic visit require 21 . Placement institution due governmental judicial authority</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Huntington 's disease</keyword>
	<keyword>Apathy</keyword>
	<keyword>Bupropion</keyword>
</DOC>